K-quarantine leader, Poonglim Pharmatech, makes additional
investment in Saemangeum
- The company diversifies its business in pharmaceutical products and
diagnostic medical devices with the investment of KRW 19.5B ($ 16.2M)
□ SDIA(Administrator Yang Choong-mo) announced on January 26
that SDIA and Poonglim Pharmatech signed an investment
agreement for constructing manufacturing facility for
pharmaceutical products and medical devices in Saemangeum,
with Jeollabuk-do Province, Gunsan City, and Korea Rural
Community Corporation.
ㅇ Twenty officials attended the signing ceremony, including
Administrator Yang Choong-mo of SDIA, vice governor of
Jeonbuk Province, Shin Wonsik, Mayor of Gunsan City, Kang
Im-joon, and Jo Hee-min, CEO of Poonglim Pharmatech.
* In order to prevent the spread of COVID-19, the number of participants
was kept to a minimum, and quarantine rules were strictly observed.
□ Poonglim Pharmatech will start constructing their 4
th plant on
132,000㎡, investing KRW 19.5 billion ($ 16.2 million) at
Saemangeum Industrial Complex in June, and will hire 70
employees.
ㅇ The company already built its 3
rd plant 33,000㎡ at
Saemangeum Industrial Complex, with an investment of
KRW 12.8 billion in 2018, and is manufacturing medical
devices, especially syringes.
ㅇ Poonglim Pharmatech is producing ophthalmic and joint
pharmaceutical products, hyaluronic acid and collagen
osteoarthritis treatments, and diagnostic medical devices at its
4
th plant. The company is going to diversify its capability to
produce pharmaceuticals and medical devices in line with the
growing medical market demand.
ㅇ The additional investment of Poonglim Pharmatech was decided
in consideration of the proximity to the 3
rd factory and key
infrastructure, such as new seaport, international airport and
railways which are being rapidly constructed.
□ Poonglim Pharmatech is a medical device manufacturing company
that supplies syringes to pharmaceutical companies and hospitals. In particular, it is a promising company that developed and
exports LDV syringes* with minimum residual volume to the
States, Europe, and Asia.
* LDV (Low Dead Volume) syringe : A special syringe with the minimum
remaining injection volume technology applied. The remaining volume per
dose of a general syringe is 84 ㎕ or more, and that of the syringe by
Poonglim Pharmatech is 4 ㎕ or less.
ㅇ They are taking the lead in giving a boost to the domestic
manufacturing of medical devices, based on ongoing R&D and
accumulated technology. They have already proven the
superiority of K-quarantine through the quality of their
products in domestic and overseas markets.
□ Jo Hee-min, CEO of Poonglim Pharmatech, revealed their
2030 goal by stating that they would become a company that
contributes to national health and national development by
expanding production not only of medical devices but also
medicines through new factories in Saemangeum, where a
bright future is expected.
□ Yang Choong-mo, Administrator of SDIA, said, “We welcome
the additional investment of Poonglim Pharmatech, which has
achieved the lofty status of K-quarantine in the context of
the COVID-19 pandemic around the world,” and he added,
“We will provide our support so that Poonglim Pharmatech can
diversify its business into the pharmaceutical sector and grow
into a global company.”
